Doravirine (DOR)

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Walter K. Kraft

Conditions

Drug Interaction PotentiationHIV InfectionsHuman Immunodeficiency VirusLatent TuberculosisRifamycins Causing Adverse Effects in Therapeutic UseTuberculosis

Phase 1

Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

CompletedNCT03332095

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2018-07-02End: 2022-05-25Updated: 2023-02-14

Doravirine, Rifapentine and Isoniazid Interaction

CompletedNCT03886701

Walter K. KraftDrug Interaction Potentiation, Human Immunodeficiency Virus, Latent Tuberculosis +1

Start: 2019-04-22End: 2019-05-20Updated: 2020-03-27

Unknown Phase

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

CompletedNCT04518228

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Tuberculosis

Start: 2021-09-01End: 2025-07-10Updated: 2025-11-12